| Feature | Description/Details (with citations) |
|---|---|
| Gene nomenclature | **Official human gene:** **PIP5K1B**; **protein:** phosphatidylinositol 4-phosphate 5-kinase type-1 beta / PIP5K1B / PIP5Kβ / PIP5KIβ; older synonym **STM7** is also associated with this beta isoform in the supplied target definition. The human Type I PIP5K family comprises three paralogs: **PIP5K1A, PIP5K1B, and PIP5K1C** (pqac-00000001, pqac-00000005, pqac-00000007). |
| Protein classification and family | PIP5K1B is a **Type I phosphatidylinositol phosphate kinase (PIP5K)**, i.e., a **lipid kinase** in the broader **PIPK family**. Type I PIPKs are the principal enzymes that synthesize most cellular and plasma-membrane **PI(4,5)P2** from **PI4P**, distinguishing them from Type II PIPKs/PIP4Ks, which mainly use **PI5P** as substrate (pqac-00000004, pqac-00000005, pqac-00000012). |
| Enzymatic reaction catalyzed | Canonical reaction: **phosphatidylinositol 4-phosphate [PI4P/PtdIns4P] + ATP → phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2/PtdIns(4,5)P2] + ADP**. This is the defining reaction of Type I PIP5Ks and is the major synthetic route for PI(4,5)P2 in most cells (pqac-00000000, pqac-00000004, pqac-00000005, pqac-00000007). |
| Substrate specificity | Primary physiological substrate is **PI4P**, phosphorylated at the **5-position** of the inositol ring. Structural/biochemical studies of Type I PIPKs show that substrate specificity is determined by a specialized **specificity loop/activation loop** and a **monophosphate-binding site**; in vitro, Type I PIPKs can also show activity toward **PI3P**, but PI4P is the main cellular substrate for PI(4,5)P2 production (pqac-00000004, pqac-00000005, pqac-00000006). |
| Primary subcellular localization | Type I PIP5Ks function mainly at the **cytoplasmic face of the plasma membrane**, where they generate the dominant pool of **PI(4,5)P2**. Family studies emphasize membrane docking through substrate recognition, electrostatic interactions with anionic lipids, and product-assisted membrane association; recent work on human PIP5KB specifically discusses cooperative membrane association on PI(4,5)P2-containing membranes (pqac-00000004, pqac-00000005, pqac-00000010). |
| Key structural features | PIP5K1B is expected to share the conserved **PIPK catalytic core** of Type I PIP5Ks, including a **protein-kinase-like fold**, a **specificity/activation loop** important for lipid-substrate recognition and localization, and a **membrane-sensing amphipathic helix behavior** within that activation loop. Structural work on Type I PIPKs also shows **side-to-side dimerization** that can enhance catalytic efficiency/allosteric regulation (pqac-00000006, pqac-00000007, pqac-00000005). |
| Major signaling pathways involved | Through generation of **PI(4,5)P2**, PIP5K1B feeds multiple pathways: **(1) PI3K-Akt signaling**, because PI(4,5)P2 is the substrate for class I PI3K to make **PI(3,4,5)P3**; **(2) PLC signaling**, because PI(4,5)P2 is cleaved to IP3 and DAG; **(3) membrane/cytoskeleton signaling**, including actin remodeling, endocytosis, and receptor signaling; and **(4) T-cell signaling**, where PIP5Kβ has a nonredundant role in immunological synapse organization (pqac-00000002, pqac-00000003, pqac-00000005, pqac-00000012). |
| Biological processes regulated | PI(4,5)P2 produced by Type I PIP5Ks regulates **actin cytoskeleton organization**, **lipid raft dynamics**, **immunological synapse assembly**, **endocytosis/exocytosis**, **ion channel and transporter regulation**, **vesicular trafficking**, and **cell migration/adhesion**. In T cells, PIP5Kβ controls recruitment of **lipid rafts** and **filamin A** to the immunological synapse; more broadly, phosphoinositide signaling organizes membrane–cytosol interfaces controlling motility and adhesion (pqac-00000003, pqac-00000005, pqac-00000010, pqac-00000011). |
| Disease associations mentioned in recent literature | Recent literature links the **PIP5K/PIP4K axis** to **cancer biology** and drug targeting, especially via altered PI(4,5)P2/PI3K signaling. A 2023 review identifies PIP5K family members as potential **drug targets in breast cancer**; broader phosphoinositide literature connects these enzymes to malignant signaling, trafficking, and cytoskeletal dysregulation. While recent papers more often emphasize **PIP5K1A** or **PIP5K1C**, PIP5K1B is part of the same disease-relevant enzymatic network and has been noted in cancer-cell phosphoinositide studies (pqac-00000001, pqac-00000008, pqac-00000010). |


*Table: This table compiles the key functional annotation points for human PIP5K1B, including nomenclature, enzyme activity, localization, structural features, pathways, and disease relevance. It is useful as a concise evidence-backed reference for interpreting the protein’s primary biochemical role.*